Giulia Gabrielli
Bologna, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells.
Journal: Science translational medicine
Published: February 04, 2026
Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE study.
Journal: Blood advances
Published: October 20, 2025
β-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer.
Journal: Cell
Published: April 17, 2025
SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapy.
Journal: Annals of hematology
Published: March 31, 2025
CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia.
Journal: Journal of cellular and molecular medicine
Published: March 29, 2025
Correction: Bertuzzi et al. Microenvironmental Traits of Classical Hodgkin's Lymphoma in Adolescents and Their Prognostic Impact. Cancers 2024, 16, 4210.
Journal: Cancers
Published: January 16, 2025
Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice.
Journal: Annals of hematology
Published: January 03, 2025
Efficacy and Safety of Frontline Single-Agent Rituximab in Extranodal Marginal Zone Lymphoma.
Journal: European journal of haematology
Published: July 09, 2024
CAR T-Cell Immunotherapy in Minority Patients with Lymphoma.
Journal: NEJM evidence
Published: May 22, 2024
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel.
Journal: Journal of hematology & oncology
Published: January 29, 2024
Last Updated: 09/26/2026